MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

VRTX · NASDAQ-GS

Vertex Pharmaceuticals Incorporated

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$490.39As of Jul 28, 2026
Market capitalization$124B
52-week range$362.50–$533.67
S&P 500 portfolio weight0.19%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$350.00-28.6% vs. reference
Average$558.78+13.9% vs. reference
High$652.00+33.0% vs. reference
19 Buy4 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 3, 2026Jun 2026
Consensus EPS$4.305 estimates
Expected range$4.01–$4.46Low to high EPS
Dec 2026$17.01Street EPS consensus
Dec 2027$18.83Street EPS consensus
Dec 2028$20.59Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+8.9% YoY$12B$11.02B
Operating income$4.17B($0.23B)
Net income$3.95B($0.54B)
Operating cash flow$3.63B($0.49B)
Capital expenditures($0.44B)($0.3B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Zacks

GSK (GSK) Beats Q2 Earnings and Revenue Estimates

Zacks

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.